Order Article Reprints

Iwamoto H, Shimose S, Noda Y, Shirono T, Niizeki T, Nakano M, Okamura S, Kamachi N, Suzuki H, Sakai M, et al. Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice. Cancers. 2021; 13(11):2786. https://doi.org/10.3390/cancers13112786

Iwamoto, Hideki, Shigeo Shimose, Yu Noda, Tomotake Shirono, Takashi Niizeki, Masahito Nakano, Shusuke Okamura, Naoki Kamachi, Hiroyuki Suzuki, Miwa Sakai, and et al. 2021. "Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice" Cancers 13, no. 11: 2786. https://doi.org/10.3390/cancers13112786

Iwamoto, H., Shimose, S., Noda, Y., Shirono, T., Niizeki, T., Nakano, M., Okamura, S., Kamachi, N., Suzuki, H., Sakai, M., Kajiwara, A., Itano, S., Tanaka, M., Yamaguchi, T., Kuromatsu, R., Koga, H., Torimura, T., & on behalf of The Kurume Liver Cancer Study Group of Japan. (2021). Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice. Cancers, 13(11), 2786. https://doi.org/10.3390/cancers13112786